Novartis abandons asthma drug after late-stage failure

17th December 2019 Uncategorised 0

The company will continue to to invest in respiratory medicines with in-market products Xolair (omalizumab) and other Phase III investigational products, QVM149 and QMF149.

More: Novartis abandons asthma drug after late-stage failure
Source: News